Garry Arthur Neil is CEO and Chairman of the Board of Avalo Therapeutics, Inc.. Currently has a direct ownership of 13,220 shares of AVTX, which is worth approximately $130,217. The most recent transaction as insider was on Jun 09, 2023, when has been sold 4,000 shares (Common Stock) at a price of $3.42 per share, resulting in proceeds of $13,680. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 13.2K
0% 3M change
0% 12M change
Total Value Held $130,217

GARRY ARTHUR NEIL Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 09 2023
BUY
Open market or private purchase
$13,680 $3.42 p/Share
4,000 Added 23.23%
13,220 Common Stock
Dec 09 2022
BUY
Open market or private purchase
$9,206 $4.42 p/Share
2,083 Added 18.43%
9,220 Common Stock
Dec 10 2021
BUY
Open market or private purchase
$6,699 $1.57 p/Share
4,267 Added 4.75%
85,639 Common Stock
Jun 10 2021
BUY
Open market or private purchase
$8,418 $2.28 p/Share
3,692 Added 4.34%
81,372 Common Stock
Dec 10 2020
BUY
Open market or private purchase
$8,206 $2.28 p/Share
3,599 Added 4.43%
77,680 Common Stock

Also insider at

ARNA
ARENA PHARMACEUTICALS INC Healthcare
CLDX
Celldex Therapeutics, Inc. Healthcare
JATT-WT
JATT Acquisition Corp
GAN

Garry Arthur Neil

CEO and Chairman of the Board
Hampton, NJ

Track Institutional and Insider Activities on AVTX

Follow Avalo Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AVTX shares.

Notify only if

Insider Trading

Get notified when an Avalo Therapeutics, Inc. insider buys or sells AVTX shares.

Notify only if

News

Receive news related to Avalo Therapeutics, Inc.

Track Activities on AVTX